A Phase 3 interventional study of HYQVIA in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 19 sites in United States. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulin G · Primary Immunodeficiency Diseases.
Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 20 in phase 3, and was the 23rd registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulin G: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 23 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2017.
This study's enrollment of 44 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 28 interventional studies. Of the 25 that completed or were terminated, 15 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
23 studies in Primary Immunodeficiency Diseases by Takeda: 2 open now, 3 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 12th registered.
Takeda’s Primary Immunodeficiency Diseases studies by the year they started, since 2002.
2 of the studies testing Immunoglobulin G in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, from their registry updates:
Among Takeda’s 23 in Primary Immunodeficiency Diseases:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to \<16 years) participants with primary immunodeficiency disease (PIDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants with PIDD who were on IV or non-HYQVIA SC treatment with immunoglobulin were enrolled and treated with HYQVIA SC with a dose or interval ramp-up period of up to six weeks. HYQVIA dose was planned to be equivalent to 100% (± 5%) of pre-study treatment. Dose frequency was one treatment interval of one week, then one treatment interval of two weeks for participants who were planned to be treated every three weeks, and one more treatment interval of three weeks for participants who were planned to be treated every four weeks.
Biological: HYQVIA
Epoch 1 was followed by Epoch 2 with HYQVIA treatment infusions given once every 3 or 4 weeks, depending on the participant's previous IV dosing schedule (for IV pretreated participants) and at the discretion of the investigator and participant (for SC-pretreated participants) up to approximately 36 months.
Biological: HYQVIA
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
Also known as: IGI 10% with rHuPH20
Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year
The rate of ASBI was defined as the mean number of ASBI per participant-year based on the United States (U.S.) Food and drugs Administration (FDA) guidance for industry to support marketing of human immune globulin intravenous (IGIV) as replacement therapy for primary humoral immunodeficiency and the European Medicines Agency (EMA) guideline on the clinical investigation of human normal immunoglobulin for SC and /or intramuscular administration. ASBI included bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess, diagnosed according to the Diagnostic Criteria for Acute Serious Bacterial Infections.
Time frame: From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)
Rate Represented as Mean Number of All Infections Per Participant-year
The rate of all infections was defined as the mean number of all infections per participant-year. Number of all infections was calculated as number of infections per participant-year.
Time frame: From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)
Epoch 2: Trough Levels of Immunoglobulin G (IgG) Total and IgG Subclasses
Time frame: Study Epoch 2, Year 1: Months 0, 6, and 12; Year 2: Months 18, 24 and 36
Epoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogens Categorized as Clostridium Tetani Toxoid and Hepatitis B Virus
Time frame: Study Epoch 2, Year 2: Months 6, 24, and 36
Epoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogen Haemophilus Influenzae B
Time frame: Study Epoch 2, Year 2: Months 6, 24, and 36
Epoch 2: Area Under the Curve Normalized for Week (AUCweek)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Epoch 2: Area Under the Curve Over the Infusion Interval (AUCTau)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Epoch 2: Apparent Clearance (CL/F)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Epoch 2: Maximum Concentration (Cmax)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Epoch 2: Minimum Concentration (Cmin)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Epoch 2: Time to Maximum Concentration (Tmax)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Epoch 2: Terminal Half-life (T 1/2)
Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Number of Participants With Serious Adverse Events (SAEs) Excluding Infections, Related and Not Related
An SAE is defined as an untoward medical occurrence that at any dose is fatal, life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. Number of participants who experienced SAEs, related or not related, was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Rate of SAEs Excluding Infections, Related and Not Related, Per Infusion
Rate of SAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of SAEs per infusion (excluding infections) was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Number of Participants With All Treatment Emergent Adverse Events (TEAEs) Excluding Infections, Related and Not Related
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced TEAEs, related or not related, was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Rate of All TEAEs Excluding Infections, Related and Not Related, Per Infusion
Rate of all TEAEs per infusion was calculated as number of any adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Number of Participants With Local TEAEs Excluding Infections, Related and Not Related
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced local TEAEs, related or not related, was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Rate of Local TEAEs Excluding Infections, Related and Not Related, Per Infusion
Rate of local TEAEs per infusion was calculated as number of local TEAEs/total number of infusions administered to participants in the analysis set. Rate of local TEAEs per infusion (excluding infections) was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Number of Participants With Systemic TEAEs Excluding Infections, Related and Not Related
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced systemic TEAEs, related or not related, was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Rate of Systemic TEAEs Excluding Infections, Related and Not Related, Per Infusion
Rate of systemic TEAEs per infusion was calculated as number of systemic TEAEs/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion (excluding infections) was reported.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Number of Participants With All Temporally Associated TEAEs Excluding Infections
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced all temporally associated TEAEs, related or not related, was reported.
Time frame: From beginning of infusion up to 72 hours post infusion
Rate of All Temporally Associated TEAEs Excluding Infections Per Infusion
Rate of all temporally associated TEAEs per infusion was calculated as number of all temporally associated TEAEs/total number of infusions administered to participants in the analysis set. Rate of all temporally associated TEAEs per infusion (excluding infections) was reported.
Time frame: From beginning of infusion up to 72 hours post infusion
Number of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.
Time frame: From beginning of infusion up to 72 hours post infusion
Rate of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections Per Infusion
Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.
Time frame: From beginning of infusion up to 72 hours post infusion
Percentage of Participants With Any TEAEs Excluding Infections
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest decimal.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Number of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20
Number of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Percentage of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20
Percentage of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once. Percentages are rounded off to whole number at the nearest decimal.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Epoch 2: Number of Infusions Per Month
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Number of Infusion Sites (Needle Sticks) Per Infusion
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Number of Infusion Sites (Needle Sticks) Per Month
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Duration of Infusion
Duration of infusion is calculated as (stop time of infusion - start time of infusion) (in Epoch 2). Duration of infusion is the time from the start of rHuPH20 infusion until the stop time of immunoglobulin infusion.
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Maximum Infusion Rate Per Site
HYQVIA treatment infusions in Epoch 2 were given at a rate of 10 milliliters per hour per site (mL/h/site) to 160 ml/h/site (body weight \[BW\] of \<40 kg) and 10 mL/h/site to 300 mL/h/site (BW of ≥40 kg).
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Infusion Volume Per Site
Infusion volume per site is calculated as (actual IgG volume (mL) / total number of infusion sites used).
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Percentage of Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE
Percentages are rounded off to whole number at the nearest decimal.
Time frame: Study Epoch 2: Up to 36 months
Epoch 1: Number of Weeks to Reach Final Dose Interval
Time frame: Epoch 1 (up to 6 weeks)
Epoch 2: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2
Percentages are rounded off to whole number at the nearest decimal. Percentages may sum up to more than 100% as assigned treatment interval could be changed during the study.
Time frame: Study Epoch 2: Up to 36 months
Epoch 2: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 for 12 Months
Percentages are rounded off to whole number at the nearest decimal.
Time frame: Study Epoch 2: Up to 12 months
Health-related Quality of Life (HRQoL): Change From Baseline in Pediatric Quality of Life Inventory (Peds-QL) Score
Peds-QL=generic questionnaire developed and validated to measure HRQoL among pediatric population. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (Age groups: Toddler (2-4years),Young child (5-7years),Child (8-12years), and Teens (13-\<16years). Depending on the participants age, questionnaire may be completed by participant or parent/caregiver as appropriate. Items were scored on a 5-point Likert scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). All Scores were transformed on a total scale from 0-100 where, 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicating better health status. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
HRQoL: Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Score
The EQ-5D is a validated, self-administered assessment of overall health consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participants were asked to describe their health state that day by choosing 1 of 3 responses that reflect the levels of severity for each of the five dimensions: no problems, some or moderate problems, or extreme problems. The domain scores are calculated with higher scores indicating worsening health status. The EQ-5D also includes a standard vertical 20-cm visual analogue scale (similar to a thermometer) for recording a participant's rating of their current HRQoL state, which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Treatment Preference and Satisfaction: Change From Baseline in Assessment of Life Quality Index (LQI) Score
The LQI is a validated questionnaire assessing participant perceptions of their HRQoL and their treatment specifically among participants who use IgG therapy. This questionnaire covers 4 domains: treatment interferences, therapy-related problems, therapy setting, and treatment costs. The LQI domains are scored from 0 to 100, with higher scores associated with better IgG treatment satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Treatment Preference and Satisfaction: Change From Baseline in Assessment of Treatment Satisfaction and Medication Questionnaire (TSQM-9) Score
The TSQM-9 is a 9-item, validated, self-administered instrument to assess participant satisfaction with medication, which assesses 3 domains: effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Treatment Preference and Satisfaction: Number of Participants Who Completed Treatment Preference Questionnaire
The treatment preference questionnaire, internally developed by the study sponsor, is a self-administered, non-validated scale assessing participant preference for various attributes of immunoglobulin G (IgG) therapy.End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
Time frame: Study Epoch 2: Up to Month 36
Health Resource Utilization: Days Not Able to go to School or Work, or to Perform Normal Daily Activities
Days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses were calculated as days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Health Resource Utilization: Days on Antibiotics
Days on antibiotics were calculated as days on antibiotics per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Health Resource Utilization: Number of Hospitalizations
Number of hospitalizations, indication for the hospitalization (infection or non-infection) were calculated as number of hospitalizations, indication for the hospitalization (infection or non-infection) per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Health Resource Utilization: Number of Days Hospitalized Per Participant-Year
Number of days hospitalized were calculated as number of days hospitalized per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)
Participants took part in the study at 19 investigative sites in the United States from 25 September 2017 to 20 July 2022. Pediatric participants with a diagnosis of primary immunodeficiency diseases (PIDD) were enrolled in this study.
| Milestone | Epoch 1 | Epoch 2 |
|---|---|---|
| Started | 44 | 0 |
| Completed | 43 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Epoch 1 | Epoch 2 |
|---|---|---|
| Started | 0 | 43 |
| Completed | 0 | 34 |
| Not completed | 0 | 9 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 6 |
| Withdrew: Reason not specified | 0 | 1 |
The rate of ASBI was defined as the mean number of ASBI per participant-year based on the United States (U.S.) Food and drugs Administration (FDA) guidance for industry to support marketing of human immune globulin intravenous (IGIV) as replacement therapy for primary humoral immunodeficiency and the European Medicines Agency (EMA) guideline on the clinical investigation of human normal immunoglobulin for SC and /or intramuscular administration. ASBI included bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess, diagnosed according to the Diagnostic Criteria for Acute Serious Bacterial Infections.
| ASBI per participant-year | Epoch 1 + Epoch 2 |
|---|---|
| Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year | 0.04 ± 0.027 |
The rate of all infections was defined as the mean number of all infections per participant-year. Number of all infections was calculated as number of infections per participant-year.
| infections per participant-year | Epoch 1 + Epoch 2 |
|---|---|
| Rate Represented as Mean Number of All Infections Per Participant-year | 3.12 ± 0.450 |
| grams per liter (g/L) | Epoch 2 |
|---|---|
| IgG Total: Month 0 | 10.381 ± 2.9191 |
| IgG Total: Month 6 | 9.199 ± 1.9577 |
| IgG Total: Month 12 | 9.214 ± 1.9800 |
| IgG Total: Month 18 | 13.80 ± NA |
| IgG Total: Month 24 | 10.80 ± NA |
| IgG Total: Month 36 | 13.50 ± NA |
| IgG Subclass 1: Month 0 | 5.888 ± 2.7193 |
| IgG Subclass 1: Month 6 | 5.317 ± 1.4887 |
| IgG Subclass 1: Month 12 | 5.284 ± 1.2103 |
| IgG Subclass 1: Month 18 | 7.590 ± NA |
| IgG Subclass 1: Month 24 | 7.710 ± NA |
| IgG Subclass 2: Month 0 | 3.311 ± 0.6833 |
| IgG Subclass 2: Month 6 | 3.156 ± 0.6694 |
| IgG Subclass 2: Month 12 | 3.106 ± 0.5839 |
| IgG Subclass 2: Month 18 | 3.480 ± NA |
| IgG Subclass 2: Month 24 | 3.510 ± NA |
| IgG Subclass 3: Month 0 | 0.534 ± 0.2838 |
| IgG Subclass 3: Month 6 | 0.508 ± 0.2545 |
| IgG Subclass 3: Month 12 | 0.507 ± 0.2799 |
| IgG Subclass 3: Month 18 | 0.360 ± NA |
| IgG Subclass 3: Month 24 | 0.430 ± NA |
| IgG Subclass 4: Month 0 | 0.2998 ± 0.26802 |
| IgG Subclass 4: Month 6 | 0.3161 ± 0.32899 |
| IgG Subclass 4: Month 12 | 0.3118 ± 0.32790 |
| IgG Subclass 4: Month 18 | 0.9380 ± NA |
| IgG Subclass 4: Month 24 | 1.4560 ± NA |
| international unit per milliliter(IU/mL) | Epoch 2 |
|---|---|
| Clostridium Tetani Toxoid Antibody: Month 6 | 1.685 ± 0.6793 |
| Clostridium Tetani Toxoid Antibody: Month 24 | 2.450 ± NA |
| Clostridium Tetani Toxoid Antibody: Completion/ Termination (Month 36) | 1.598 ± 0.5889 |
| Hepatitis B Virus Antibody: Month 6 | 199.6 ± 122.97 |
| Hepatitis B Virus Antibody: Month 24 | 146.0 ± NA |
| Hepatitis B Virus Antibody: Completion/ Termination (Month 36) | 256.7 ± 219.53 |
| milligrams per liter (mg/L) | Epoch 2 |
|---|---|
| Month 6 | 1.839 ± 1.5222 |
| Month 24 | 1.810 ± NA |
| Completion/Termination (Month 36) | 1.678 ± 0.8009 |
| grams*day per liter (g*day/L) | Epoch 2 |
|---|---|
| Epoch 2: Area Under the Curve Normalized for Week (AUCweek) | 74.57 ± 19.4 |
| g*day/L | Epoch 2 |
|---|---|
| Epoch 2: Area Under the Curve Over the Infusion Interval (AUCTau) | 288.8 ± 21.7 |
| milliliters per day (mL/day) | Epoch 2 |
|---|---|
| Epoch 2: Apparent Clearance (CL/F) | 56.45 ± 61.4 |
| g/L | Epoch 2 |
|---|---|
| Epoch 2: Maximum Concentration (Cmax) | 12.94 ± 17.4 |
| g/L | Epoch 2 |
|---|---|
| Epoch 2: Minimum Concentration (Cmin) | 8.571 ± 25.6 |
| days | Epoch 2 |
|---|---|
| Epoch 2: Time to Maximum Concentration (Tmax) | 4.20 (0.0 to 26.9) |
| days | Epoch 2 |
|---|---|
| Epoch 2: Terminal Half-life (T 1/2) | 44.98 ± 45.9 |
An SAE is defined as an untoward medical occurrence that at any dose is fatal, life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. Number of participants who experienced SAEs, related or not related, was reported.
| Participants | Epoch 1 | Epoch 2 |
|---|---|---|
| SAE: Related | 0 | 0 |
| SAE: Not Related | 0 | 1 |
Rate of SAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of SAEs per infusion (excluding infections) was reported.
| SAEs per infusion | Epoch 1 | Epoch 2 |
|---|---|---|
| SAE: Related | 0.0 | 0.0 |
| SAE: Not Related | 0.0 | 0.002 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced TEAEs, related or not related, was reported.
| Participants | Epoch 1 | Epoch 2 |
|---|---|---|
| TEAE: Related | 25 | 31 |
| TEAE: Not Related | 16 | 36 |
Rate of all TEAEs per infusion was calculated as number of any adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.
| adverse reaction event per infusion | Epoch 1 | Epoch 2 |
|---|---|---|
| TEAE: Related | 0.675 | 0.397 |
| TEAE: Not Related | 0.270 | 0.262 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced local TEAEs, related or not related, was reported.
| Participants | Epoch 1 | Epoch 2 |
|---|---|---|
| Local TEAE: Related | 22 | 28 |
| Local TEAE: Not Related | 2 | 6 |
Rate of local TEAEs per infusion was calculated as number of local TEAEs/total number of infusions administered to participants in the analysis set. Rate of local TEAEs per infusion (excluding infections) was reported.
| local TEAEs per infusion | Epoch 1 | Epoch 2 |
|---|---|---|
| Local TEAE: Related | 0.460 | 0.212 |
| Local TEAE: Not Related | 0.016 | 0.013 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced systemic TEAEs, related or not related, was reported.
| Participants | Epoch 1 | Epoch 2 |
|---|---|---|
| Systemic TEAE: Related | 12 | 20 |
| Systemic TEAE: Not Related | 16 | 33 |
Rate of systemic TEAEs per infusion was calculated as number of systemic TEAEs/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion (excluding infections) was reported.
| systemic TEAEs per infusion | Epoch 1 | Epoch 2 |
|---|---|---|
| Systemic TEAE: Related | 0.214 | 0.185 |
| Systemic TEAE: Not Related | 0.254 | 0.250 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced all temporally associated TEAEs, related or not related, was reported.
| Participants | Epoch 1 | Epoch 2 |
|---|---|---|
| Number of Participants With All Temporally Associated TEAEs Excluding Infections | 27 | 35 |
Rate of all temporally associated TEAEs per infusion was calculated as number of all temporally associated TEAEs/total number of infusions administered to participants in the analysis set. Rate of all temporally associated TEAEs per infusion (excluding infections) was reported.
| temporally associated TEAEs per infusion | Epoch 1 | Epoch 2 |
|---|---|---|
| Rate of All Temporally Associated TEAEs Excluding Infections Per Infusion | 0.722 | 0.460 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.
| Participants | Epoch 1 | Epoch 2 |
|---|---|---|
| Number of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections | 27 | 35 |
Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.
| related temporally TEAEs per infusion | Epoch 1 | Epoch 2 |
|---|---|---|
| Rate of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections Per Infusion | 0.762 | 0.482 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | Epoch 1 | Epoch 2 |
|---|---|---|
| Percentage of Participants With Any TEAEs Excluding Infections | 65.9 | 93.0 |
Number of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once.
| Participants | Epoch 1 + Epoch 2 |
|---|---|
| Number of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20 | 1 |
Percentage of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once. Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | Epoch 1 + Epoch 2 |
|---|---|
| Percentage of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20 | 2.3 |
| infusions per month | Epoch 2 |
|---|---|
| Epoch 2: Number of Infusions Per Month | 1.10 (1.0 to 1.5) |
| infusion sites per infusion | Epoch 2 |
|---|---|
| Epoch 2: Number of Infusion Sites (Needle Sticks) Per Infusion | 1.83 ± 0.366 |
| infusion sites per month | Epoch 2 |
|---|---|
| Epoch 2: Number of Infusion Sites (Needle Sticks) Per Month | 2.17 (1.1 to 2.9) |
Duration of infusion is calculated as (stop time of infusion - start time of infusion) (in Epoch 2). Duration of infusion is the time from the start of rHuPH20 infusion until the stop time of immunoglobulin infusion.
| minutes (mins) | Epoch 2 |
|---|---|
| Epoch 2: Duration of Infusion | 85.0 (45 to 215) |
HYQVIA treatment infusions in Epoch 2 were given at a rate of 10 milliliters per hour per site (mL/h/site) to 160 ml/h/site (body weight \[BW\] of \<40 kg) and 10 mL/h/site to 300 mL/h/site (BW of ≥40 kg).
| milliliters per hour per site(mL/h/site) | Epoch 2 |
|---|---|
| Epoch 2: Maximum Infusion Rate Per Site | 173.5 ± 81.32 |
Infusion volume per site is calculated as (actual IgG volume (mL) / total number of infusion sites used).
| mL/site | Epoch 2 |
|---|---|
| Epoch 2: Infusion Volume Per Site | 101.3 ± 51.69 |
| infusions | Epoch 2 |
|---|---|
| Infusions That Were Discontinued | 0 |
| Infusions That Were Slowed | 0 |
| Infusions That Were Interrupted | 17 |
Percentages are rounded off to whole number at the nearest decimal.
| percentage of infusions | Epoch 2 |
|---|---|
| Infusions That Were Discontinued | 0 |
| Infusions That Were Slowed | 0 |
| Infusions That Were Interrupted | 2.69 |
| weeks | Epoch 1 |
|---|---|
| Epoch 1: Number of Weeks to Reach Final Dose Interval | 6.14 (3.0 to 6.6) |
Percentages are rounded off to whole number at the nearest decimal. Percentages may sum up to more than 100% as assigned treatment interval could be changed during the study.
| percentage of participants | Epoch 2 |
|---|---|
| Every 3 Weeks | 18.6 |
| Every 4 Weeks | 83.7 |
Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | Epoch 2 |
|---|---|
| Epoch 2: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 for 12 Months | 74.4 |
Peds-QL=generic questionnaire developed and validated to measure HRQoL among pediatric population. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (Age groups: Toddler (2-4years),Young child (5-7years),Child (8-12years), and Teens (13-\<16years). Depending on the participants age, questionnaire may be completed by participant or parent/caregiver as appropriate. Items were scored on a 5-point Likert scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). All Scores were transformed on a total scale from 0-100 where, 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicating better health status. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
| score on a scale | Epoch 1 + Epoch 2 |
|---|---|
| Baseline: 2-4 years | 72.67 ± 12.969 |
| Baseline: 5-7 years | 77.29 ± 18.908 |
| Baseline: 8-12 years | 75.42 ± 17.227 |
| Baseline: 13-<16 years | 76.09 ± 7.894 |
| Change From Baseline at Epoch 2 Month 12: 2-4 years | 4.57 ± 17.134 |
| Change From Baseline at Epoch 2 Month 12: 5-7 years | -3.74 ± 15.170 |
| Change From Baseline at Epoch 2 Month 12: 8-12 years | 0.84 ± 21.050 |
| Change From Baseline at Epoch 2 Month 12: 13-<16 years | -6.09 ± 8.750 |
| Change From Baseline at Completion/ termination (Month 36): 2-4 years | 8.73 ± 18.799 |
| Change From Baseline at Completion/ termination (Month 36): 5-7 years | -26.09 ± NA |
| Change From Baseline at Completion/ termination (Month 36): 8-12 years | -5.16 ± 19.735 |
| Change From Baseline at Completion/ termination (Month 36): 13-<16 years | 3.62 ± 5.471 |
| Change From Baseline at End of Epoch 2: 2-4 years | 8.16 ± 17.730 |
| Change From Baseline at End of Epoch 2: 5-7 years | -4.59 ± 16.266 |
| Change From Baseline at End of Epoch 2: 8-12 years | -1.98 ± 14.027 |
| Change From Baseline at End of Epoch 2: 13-<16 years | -2.45 ± 8.807 |
The EQ-5D is a validated, self-administered assessment of overall health consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participants were asked to describe their health state that day by choosing 1 of 3 responses that reflect the levels of severity for each of the five dimensions: no problems, some or moderate problems, or extreme problems. The domain scores are calculated with higher scores indicating worsening health status. The EQ-5D also includes a standard vertical 20-cm visual analogue scale (similar to a thermometer) for recording a participant's rating of their current HRQoL state, which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
| score on a scale | Epoch 1 + Epoch 2 |
|---|---|
| Baseline: Visual Analogue Scale (VAS) Score | 82.84 ± 16.806 |
| Baseline: Mobility | 1.07 ± 0.258 |
| Baseline: Self-care | 1.16 ± 0.485 |
| Baseline: Usual Activities | 1.14 ± 0.413 |
| Baseline: Pain/ Discomfort | 1.28 ± 0.454 |
| Baseline: Anxiety/ Depression | 1.28 ± 0.549 |
| Change From Baseline at Epoch 2 Month 12: VAS Score | 0.64 ± 23.504 |
| Change From Baseline at Epoch 2 Month 12: Mobility | -0.09 ± 0.292 |
| Change From Baseline at Epoch 2 Month 12: Self-care | -0.12 ± 0.415 |
| Change From Baseline at Epoch 2 Month 12: Usual Activities | 0.03 ± 0.394 |
| Change From Baseline at Epoch 2 Month 12: Pain/ Discomfort | 0.18 ± 0.528 |
| Change From Baseline at Epoch 2 Month 12: Anxiety/ Depression | -0.06 ± 0.556 |
| Change From Baseline at Completion/ Termination (Month 36): VAS Score | -8.93 ± 26.993 |
| Change From Baseline at Completion/ Termination (Month 36): Mobility | 0.00 ± 0.000 |
| Change From Baseline at Completion/ Termination (Month 36): Self-care | 0.00 ± 0.000 |
| Change From Baseline at Completion/ Termination (Month 36): Usual Activities | 0.00 ± 0.535 |
| Change From Baseline at Completion/ Termination (Month 36): Pain/ Discomfort | -0.07 ± 0.594 |
| Change From Baseline at Completion/ Termination (Month 36): Anxiety/ Depression | -0.27 ± 0.594 |
| Change From Baseline at End of Epoch 2: VAS Score | -2.83 ± 24.895 |
| Change From Baseline at End of Epoch 2: Mobility | -0.07 ± 0.264 |
| Change From Baseline at End of Epoch 2: Self-care | -0.10 ± 0.374 |
| Change From Baseline at End of Epoch 2: Usual Activities | 0.00 ± 0.387 |
| Change From Baseline at End of Epoch 2: Pain/ Discomfort | 0.07 ± 0.565 |
| Change From Baseline at End of Epoch 2: Anxiety/ Depression | -0.10 ± 0.539 |
The LQI is a validated questionnaire assessing participant perceptions of their HRQoL and their treatment specifically among participants who use IgG therapy. This questionnaire covers 4 domains: treatment interferences, therapy-related problems, therapy setting, and treatment costs. The LQI domains are scored from 0 to 100, with higher scores associated with better IgG treatment satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
| score on a scale | Epoch 1 + Epoch 2 |
|---|---|
| Baseline: Treatment Interferences | 69.77 ± 17.518 |
| Baseline: Therapy-related Problems | 65.21 ± 17.080 |
| Baseline: Therapy Setting | 85.66 ± 14.610 |
| Baseline: Treatment Costs | 60.85 ± 27.310 |
| Change From Baseline at Epoch 2 Month 12: Treatment Interferences | 4.71 ± 18.419 |
| Change From Baseline at Epoch 2 Month 12: Therapy-related Problems | 4.67 ± 17.670 |
| Change From Baseline at Epoch 2 Month 12: Therapy Setting | -6.23 ± 23.189 |
| Change From Baseline at Epoch 2 Month 12: Treatment Costs | 4.55 ± 36.330 |
| Change From Baseline at Completion/Termination (Month 36): Treatment Interferences | -10.52 ± 23.850 |
| Change From Baseline at Completion/Termination (Month 36): Therapy-related Problems | -13.39 ± 31.656 |
| Change From Baseline at Completion/Termination (Month 36): Therapy Setting | -15.87 ± 27.808 |
| Change From Baseline at Completion/Termination (Month 36): Treatment Costs | -1.19 ± 32.826 |
| Change From Baseline at End of Epoch 2: Treatment Interferences | 1.49 ± 20.908 |
| Change From Baseline at End of Epoch 2: Therapy-related Problems | 0.41 ± 24.399 |
| Change From Baseline at End of Epoch 2: Therapy Setting | -10.16 ± 24.718 |
| Change From Baseline at End of Epoch 2: Treatment Costs | 4.27 ± 35.164 |
The TSQM-9 is a 9-item, validated, self-administered instrument to assess participant satisfaction with medication, which assesses 3 domains: effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
| score on a scale | Epoch 1 + Epoch 2 |
|---|---|
| Baseline: Effectiveness | 74.81 ± 15.494 |
| Baseline: Convenience | 66.15 ± 16.436 |
| Baseline: Global Satisfaction | 79.07 ± 16.525 |
| Change From Baseline at Epoch 2, Month 12: Effectiveness | 6.40 ± 16.204 |
| Change From Baseline at Epoch 2, Month 12: Convenience | 2.19 ± 19.834 |
| Change From Baseline at Epoch 2, Month 12: Global Satisfaction | 4.76 ± 18.529 |
| Change From Baseline at Completion/ termination (Month 36): Effectiveness | -12.70 ± 33.577 |
| Change From Baseline at Completion/ termination (Month 36): Convenience | -7.14 ± 20.375 |
| Change From Baseline at Completion/ termination (Month 36): Global Satisfaction | -17.35 ± 36.283 |
| Change From Baseline at end of Epoch 2: Effectiveness | 3.52 ± 20.591 |
| Change From Baseline at end of Epoch 2: Convenience | -0.81 ± 20.244 |
| Change From Baseline at end of Epoch 2: Global Satisfaction | -0.17 ± 24.406 |
The treatment preference questionnaire, internally developed by the study sponsor, is a self-administered, non-validated scale assessing participant preference for various attributes of immunoglobulin G (IgG) therapy.End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).
| Participants | Epoch 2 |
|---|---|
| Month 12 | 34 |
| Completion/ Termination (Month 36) | 14 |
| End of Epoch 2 | 42 |
Days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses were calculated as days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
| days per participant-year | Epoch 1 + Epoch 2 |
|---|---|
| Health Resource Utilization: Days Not Able to go to School or Work, or to Perform Normal Daily Activities | 4.28 |
Days on antibiotics were calculated as days on antibiotics per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
| days per participant-year | Epoch 1 + Epoch 2 |
|---|---|
| Health Resource Utilization: Days on Antibiotics | 26.77 |
Number of hospitalizations, indication for the hospitalization (infection or non-infection) were calculated as number of hospitalizations, indication for the hospitalization (infection or non-infection) per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
| hospitalizations per participant-year | Epoch 1 + Epoch 2 |
|---|---|
| Health Resource Utilization: Number of Hospitalizations | 0.08 |
Number of days hospitalized were calculated as number of days hospitalized per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.
| days per participant-year | Epoch 1 + Epoch 2 |
|---|---|
| Health Resource Utilization: Number of Days Hospitalized Per Participant-Year | 0.21 |
Collected over From first dose of study drug up to EOS (up to 4 years 9 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoch 1 | 0/44 (0%) | 1/44 (2.3%) | 28/44 (63.6%) |
| Epoch 2 | 0/43 (0%) | 3/43 (7%) | 40/43 (93%) |
| Event | Epoch 1 | Epoch 2 |
|---|---|---|
| Adenovirus infectionInfections and infestations | 0/44 | 1/43 |
| Clostridium difficile colitisInfections and infestations | 0/44 | 1/43 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/44 | 1/43 |
| PneumoniaInfections and infestations | 1/44 | 0/43 |
| Event | Epoch 1 | Epoch 2 |
|---|---|---|
| HeadacheNervous system disorders | 7/44 | 16/43 |
| SinusitisInfections and infestations | 4/44 | 16/43 |
| Infusion site painGeneral disorders | 10/44 | 15/43 |
| PyrexiaGeneral disorders | 0/44 | 12/43 |
| Infusion site erythemaGeneral disorders | 5/44 | 10/43 |
| Infusion site extravasationGeneral disorders | 2/44 | 10/43 |
| Infusion site pruritusGeneral disorders | 3/44 | 10/43 |
| Infusion site swellingGeneral disorders | 3/44 | 9/43 |
| Upper respiratory tract infectionInfections and infestations | 1/44 | 8/43 |
| Viral upper respiratory tract infectionInfections and infestations | 2/44 | 8/43 |
Full Analysis Set (FAS) included all participants who provided informed consent, and met enrollment eligibility.
| Age, Continuous(years) | Epoch 1 |
|---|---|
| Mean | 9.0 ± 3.63 |
| Sex: Female, Male(Participants) | Epoch 1 |
|---|---|
| Female | 18 |
| Male | 26 |
| Ethnicity (NIH/OMB)(Participants) | Epoch 1 |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 39 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Epoch 1 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 40 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | Epoch 1 |
|---|---|
| United States | 44 |
| Height(cm) | Epoch 1 |
|---|---|
| Mean | 133.60 ± 24.024 |
| Weight(kg) | Epoch 1 |
|---|---|
| Mean | 37.78 ± 19.858 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2017 to primary completion in Jul 2022, 57 months.
Results were first posted in Oct 2023, 1 year 3 months after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 57 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulin G · Hyaluronoglucosaminidase
Primary Immunodeficiency Diseases →